Anzeige
+++40 Mio. USD Staatsaufträge bis 2029, doch die Aktie notiert noch bei 0,67 CAD+++
Portfolio Tracker
Dein Depot in Echtzeit – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige
EQS-News

Sino Biological Launches 4RISE(TM) High-Throughput Wet-Lab Services to Accelerate AI-Driven Drug Discovery 13.11.2026, 16:39 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Sino Biological / Key word(s): Financial
Sino Biological Launches 4RISE(TM) High-Throughput Wet-Lab Services to Accelerate AI-Driven Drug Discovery

13.11.2026 / 16:39 CET/CEST
The issuer is solely responsible for the content of this announcement.


HOUSTON, TX - November 13, 2026 (NEWMEDIAWIRE) - AI-driven protein design is accelerating the discovery of novel protein binders, but experimental validation remains essential to determine whether computational designs translate into meaningful target interactions. To bridge this gap, Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, announced its 4RISE™ high-throughput wet-lab validation services for AI-designed protein binders.

The services feature 3-hour cell-free expression, AI-ready binding data in as little as 3 days, and real-time API access to structured target-binding data, helping AI-focused life sciences researchers move faster and gain deeper insights. Designed for iterative AI-driven discovery, 4RISE™ combines rapid experimental turnaround, scalable screening workflows, and structured data delivery to support continuous design-test-learn cycles.

"3 Hours" and "3 Days"

Sino Biological’s XPressMAX™ Cell-Free Protein Synthesis (CFPS) platform enables recombinant protein synthesis in just 3 hours, with expression success rates exceeding 99% in established workflows. Supporting the synthesis of miniproteins, VHHs, scFvs, Fabs, enzymes, and cytokines, the platform accelerates experimental testing of AI-designed protein candidates, enabling faster feedback and design iterations.

Using Carterra high-throughput SPR, Biacore SPR, and Octet BLI, 4RISE™ delivers high-throughput binding screening, kinetic analysis, and affinity determination for candidate protein. Combined with CFPS, the workflow delivers sequence-to-AI-ready binding data in as little as 3 days. Structured binding data are accessible in real time via API, enabling seamless data retrieval for downstream research and analysis.

4 Rapid Screening Services of AI-designed Binders

To support diverse research needs in AI-driven binder discovery, 4RISE™ offers flexible screening and characterization workflows tailored to different candidate formats and validation objectives. Rapid Hit Discovery identifies binding-positive miniproteins and VHHs through crude-supernatant screening. Comparative Binder Screening evaluates purified candidates under standardized conditions to support candidate prioritization. Affinity & Kinetic Characterization provides quantitative binding insights for lead selection, while Specialized Binder Expression & Validation supports diverse binder formats through tailored mammalian expression and binding analysis.

Beyond binding, 4RISE™ also provides 20+ developability assays, 1,000+ protein bioactivity assays, and 10+ cell-based functional assays, supporting in-depth candidate evaluation and design optimization.

Proven Experience

Sino Biological works with AI companies on wet-lab validation for AI-designed antibody discovery, de novo binder design, and computational protein engineering. 4RISE™ wet-lab validation has supported studies published in Science, Nature Communications, Scientific Reports, and other high-impact journals.

“AI-designed molecules need reliable wet-lab experimental evidence to demonstrate their potential,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc. “Our integrated capabilities provide the high-quality data researchers need to evaluate candidates quickly, shorten design cycles, and turn promising discoveries into real-world applications.”

Explore 4RISE™ High-Throughput Wet-Lab Validation Services Now!

About Sino Biological

Sino Biological is a global biotechnology company specializing in high-quality recombinant proteins, antibodies, and customized research services. Serving researchers in more than 90 countries, Sino Biological supports basic research, drug discovery, vaccine development, and diagnostics through its comprehensive product portfolio, proprietary quality systems, and innovative research platforms.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on Sino Biological management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, over which Sino Biological has no control. Sino Biological assumes no obligation to update these forward-looking statements and does not intend to do so.

For media inquiries or partnership opportunities, please contact:
Sino Biological, Inc.
gmo@sinobiological.cn
www.sinobiological.com

View the original release on www.newmediawire.com


News Source: Sino Biological


13.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Sino Biological
United States
ISIN: CNE100004Q23
EQS News ID: 2434792

 
End of News EQS News Service

2434792  13.11.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer